Pharma giant Mylan has agreed to pay the federal government $465 million to settle questions of how the company’s EpiPen was classified under the Medicaid Drug Rebate Program. Mylan announced the deal late on Friday afternoon. …
HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange
Mylan is the worst-performing stock in the 61-member S&P 500 health-care index over the past 12 months with a 39 percent slump. Perrigo Co., another maker of generics, saw the second-biggest decline at 32 percent, while the …
Cecil-based generic drug maker Mylan Inc. yesterday reported a $1.38 billion loss for the quarter ended Dec. 31 and announced a restructuring that includes shrinking operations, selling the rights to its hypertension drug and the …
Generic drug firm Mylan has offered to buy over-the-counter rival Perrigo in a cash and stock deal that would create a pharmaceutical powerhouse. The global drug firm is offering nearly $30bn (£20bn; €28bn) for Ireland-based Perrigo, …
The drugmaker's shares rallied Monday following Friday's settlement with the Justice Department, resolving claims by Medicaid that Mylan overcharged the government health program for the allergy shot. That helped erase some of the …
Coury. Be the first to know - Join our Facebook page. Teva offered to buy all outstanding Mylan shares for $82, some 48 percent above its March 10 price, in a halfcash, half-stock deal that it said would lead to $2b. in cost savings. Scooping …
NEW YORK — Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. …
This week, companies like Allergan AGN, Teva TEVA and Mylan MYL were in the limelight. While Mylan and Teva …